
Chinese Tech Stocks WuXi Biologics Kingdee
WuXi Biologics (2269-hk) & Kingdee (268-hk), the two Chinese tech stocks, have shown promising bullish signals...
Share this:
Source: TradingView, Gain Capital
Kingdee (268.hk): Strong Bullish Momentum
Kingdee (268.hk), a software company, issued a profit warning in early July, pointing out that it expects to record a 1H net loss of 200 - 300 million yuan compared with a net profit of 110 million yuan last year. However, its share price showed resilience as investor continue to chase technology stocks.
Kingdee's rally, after breaking above a 2-year consolidation range, remains solid. For the stock to keep its strong bullish momentum, the level at $19.70 is expected to act as the nearest support. The 1st and 2nd resistances are expected to be located at $25.30 and $27.00. Alternatively, losing $19.70 might suggest a deeper price correction to $17.00.
Source: TradingView, Gain Capital
Related tags:
Latest market news
View more newsThe complete CFD trading experience
Award-winning platforms, competitive spreads, low commissions and dedicated support.
We live and breathe the markets and are dedicated to helping traders realise their ambitions as we continue to set the industry bar.
Economic calendar
Web Trader platform
Our sophisticated web-based platform is packed with features.

Nikkei threatens breakout as tech rebound broadens
Breakouts across the SOX and Nasdaq are being matched by rebounds across Asia, with the Nikkei now threatening to join the move.

S&P 500, Nasdaq 100 Forecast for the Week Ahead
A hawkish Fed and 10-Year Notes on the verge of a push above 5%, yet stocks have so far shrugged off that fear. But can it continue?

Hang Seng Tech rout nears make-or-break zone
The technical damage is clear, but with Hang Seng Tech now deeply stretched and approaching major support, the risk-reward is becoming more two-sided.
StoneX Europe Ltd may make third party material available on this website which may contain information included but not limited to the conditions of financial markets. The material is for information purposes only and does not contain, and should not be construed as containing, investment advice and/or investment recommendation and/or an investment research and/or an offer of or solicitation for any transactions in financial instruments; any decision to enter into a specific transaction shall be made by the client following an assessment by him/her of their situation.
StoneX Europe Ltd makes no representation or warranty and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplied. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. We are not under any obligation to update any such material. Any opinion made may be personal to the author and may not reflect the opinion of StoneX Europe Ltd.







